Pulmonx Co. (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 5,779 Shares

Pulmonx Co. (NASDAQ:LUNG) insider Geoffrey Beran Rose sold 5,779 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.13, for a total value of $41,204.27. Following the completion of the transaction, the insider now owns 285,278 shares in the company, valued at $2,034,032.14. The trade was a 1.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Pulmonx Price Performance

LUNG stock opened at $8.19 on Thursday. The business has a 50 day moving average price of $6.93 and a 200 day moving average price of $6.93. The stock has a market cap of $325.93 million, a price-to-earnings ratio of -5.69 and a beta of 0.50. Pulmonx Co. has a fifty-two week low of $5.46 and a fifty-two week high of $10.01. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The firm had revenue of $23.77 million during the quarter, compared to analysts’ expectations of $22.29 million. Equities research analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Citigroup reissued a “neutral” rating and set a $7.50 price objective (down from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Wells Fargo & Company dropped their target price on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Pulmonx presently has an average rating of “Moderate Buy” and a consensus price target of $12.75.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new position in Pulmonx during the third quarter worth $537,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Pulmonx during the third quarter worth about $480,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Pulmonx by 5.2% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company’s stock worth $9,238,000 after buying an additional 55,279 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Pulmonx by 5.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 313,169 shares of the company’s stock worth $2,596,000 after buying an additional 15,543 shares during the period. Finally, FMR LLC lifted its position in Pulmonx by 11.2% during the third quarter. FMR LLC now owns 5,872,882 shares of the company’s stock worth $48,686,000 after buying an additional 591,859 shares during the period. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.